Can I take Bōndia if I am post-menopausal?Updated 3 months ago

Bōndia is a synbiotic medical food formulated for the dietary management of osteopenia and bone loss. Our 12-month, double-blind, placebo-controlled clinical trial—published in Osteoporosis International—studied 286 women within 1–6 years after menopause. In this study, the subgroup of women with osteopenia who took Bōndia improved their bone density by 85% versus placebo. Pre-menopausal women, men, women with osteoporosis, and women more than six years post-menopause were not included in the trial.

This population was chosen because the years immediately after menopause are when women typically lose bone most rapidly. During this time, the balance between osteoclasts (bone-resorbing cells) and osteoblasts (bone-building cells) shifts dramatically. Preclinical research has shown that Bōndia reduces osteoclast activity, indicating it may help protect bone density in populations outside of those studied. To further evaluate this, Sōlaria Biō is collaborating with the Marcus Institute for Aging Research on the STARS trial (Synbiotic to Attenuate Resorption of the Skeleton), which is studying Bōndia in women over 60.

Bōndia is generally recognized as safe (GRAS). In clinical trials, there was no difference in side effects between placebo and Bōndia, indicating that it is safe and well tolerated. We recommend discussing Bōndia with your healthcare provider—especially if you fall outside the group studied in our clinical trial.